Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

4.3%

1 terminated out of 23 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

22%

5 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed with results

Key Signals

1 with results83% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (4)
Early P 1 (2)
P 1 (7)
P 2 (4)
P 3 (2)
P 4 (3)

Trial Status

Unknown9
Completed5
Recruiting5
Active Not Recruiting2
Not Yet Recruiting1
Terminated1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07488897Phase 1Recruiting

RIG 101 Trial in Healthy Adults and Adults With Asthma

NCT03455972Phase 1Active Not RecruitingPrimary

Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

NCT06751433Phase 1Recruiting

Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars

NCT06244537Not ApplicableRecruitingPrimary

Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer

NCT07085195Early Phase 1Not Yet Recruiting

A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease

NCT06596057Early Phase 1Active Not RecruitingPrimary

Safety and Efficacy of CD19 CAR-T/CAR-NK Cells

NCT05556889Not ApplicableRecruitingPrimary

Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block

NCT02018250Phase 1CompletedPrimary

Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)

NCT05349552Recruiting

Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites

NCT04852068Phase 3Unknown

A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)

NCT06066840Phase 4UnknownPrimary

Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

NCT05247957Not ApplicableTerminatedPrimary

NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03820596Phase 1CompletedPrimary

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

NCT04994210Phase 2UnknownPrimary

Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

NCT04646590Phase 3Unknown

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

NCT05140616Phase 1UnknownPrimary

Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD

NCT04621123Phase 2Completed

Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients

NCT05021276Phase 4UnknownPrimary

Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD

NCT05008666Phase 2UnknownPrimary

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

NCT04785170Not ApplicableCompletedPrimary

Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals

Scroll to load more

Research Network

Activity Timeline